MGF (Mechano Growth Factor) Dosage Guide

Evidence-based protocols for the muscle satellite cell activator — PEG-MGF dosing, intramuscular injection technique, IGF-1 LR3 sequential stacking, cycling, and safety.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

What Is MGF (Mechano Growth Factor)?

MGF (Mechano Growth Factor) is a splice variant of the IGF-1 gene — specifically the IGF-1Ec isoform in humans. It is produced locally in muscle tissue in response to mechanical stress such as resistance exercise or physical damage. MGF is the body's natural muscle repair signal: when you train hard enough to cause micro-damage, your muscle fibers produce MGF to activate satellite cells (muscle stem cells) and initiate the repair and growth process.

The research peptide versions are standard MGF (synthetic IGF-1Ec) and PEG-MGF (PEGylated Mechano Growth Factor). Standard MGF has an extremely short half-life of just minutes, making it impractical for most use cases. PEG-MGF has polyethylene glycol (PEG) attached, extending the half-life to several hours or days and making it the preferred form for exogenous administration.

What makes MGF unique among growth factor peptides is its mechanism of action. While IGF-1 LR3 primarily promotes hypertrophy (growth of existing muscle fibers through increased protein synthesis), MGF activates satellite cells — promoting their proliferation and differentiation into new muscle nuclei. This is the distinction between hyperplasia (creating new muscle nuclei, which MGF facilitates) and hypertrophy (growing existing fibers, which IGF-1 drives). MGF works first as the repair signal, then IGF-1 takes over for the growth phase.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

Dosing information in this guide is derived from published research and community protocols.

Key Characteristics:

Splice variant of IGF-1 — specifically the IGF-1Ec isoform in humans, produced locally in muscle tissue in response to mechanical stress
Satellite cell activator — activates muscle stem cells (satellite cells), promoting proliferation and differentiation into new muscle nuclei — hyperplasia potential
Two forms available — Standard MGF (half-life: minutes) and PEG-MGF (PEGylated, half-life: hours to days) — PEG-MGF is the practical choice
Localized action — best administered via intramuscular injection into the target muscle for localized satellite cell recruitment
Exercise-dependent — MGF amplifies the natural repair signal triggered by mechanical damage; training stimulus is required for optimal effect
Sequential with IGF-1 — MGF acts first (repair signal, satellite cell activation) then IGF-1 takes over (growth signal, protein synthesis) — they are complementary, not redundant

New to peptides? Start with the Beginner's Guide to Peptides.

MGF vs. IGF-1: Key Differences

Understanding the difference between MGF and IGF-1 is essential for proper protocol design. They are related — both are products of the IGF-1 gene — but they serve fundamentally different biological roles in the muscle repair and growth cascade. Using them correctly (sequentially, not simultaneously) is the key to maximizing their combined potential.

Parameter	MGF / PEG-MGF	IGF-1 LR3
Primary Mechanism	Satellite cell activation (proliferation of muscle stem cells)	Protein synthesis & cell hypertrophy (growth of existing muscle)
Biological Role	Repair signal — first responder after muscle damage	Growth signal — promotes growth after repair begins
Growth Type	Hyperplasia potential (new muscle nuclei)	Hypertrophy (larger existing fibers)
Gene Origin	IGF-1Ec splice variant	IGF-1 with extended half-life modification
Production Site	Locally in damaged muscle tissue	Primarily liver (systemic) + local tissue
Exercise Dependency	High — requires mechanical damage signal	Moderate — works with or without exercise stimulus
Injection Route	Intramuscular (localized, into target muscle)	Subcutaneous or intramuscular (systemic or localized)
Typical Dosing	PEG-MGF: 200–400 mcg IM, 2–3x/week	20–80 mcg SubQ/IM, daily or on training days
Best Used	Post-workout (to amplify repair signal)	Post-workout or morning (to drive protein synthesis)

The natural sequence matters. In the body, mechanical damage triggers MGF production first (satellite cell activation and proliferation). Then, as repair progresses, IGF-1 expression increases to drive protein synthesis and hypertrophy in the newly created muscle nuclei. The most effective exogenous protocol mimics this sequence: PEG-MGF post-workout, then IGF-1 LR3 hours later or on off-days.

How MGF Dosage Is Determined

MGF dosing is primarily informed by preclinical research on satellite cell biology and community-derived protocols. Unlike some peptides with extensive human clinical dose-response data, MGF's dosing landscape is built on a strong foundation of mechanistic science (we understand exactly what MGF does at the cellular level) combined with practical experience from the research community.

Preclinical Satellite Cell Research

The biology of MGF is well-characterized. Studies by Goldspink, Yang, and colleagues demonstrated that MGF is produced locally in muscle tissue following mechanical overload and activates satellite cells through autocrine/paracrine signaling. The IGF-1Ec splice variant (MGF) specifically upregulates satellite cell proliferation markers, distinct from the IGF-1Ea isoform that primarily drives hypertrophy. This mechanistic understanding forms the scientific basis for localized IM injection protocols.

PEGylation and Half-Life Extension

Standard MGF's half-life of just minutes makes it impractical for most research use. PEGylation (attaching polyethylene glycol chains) extends the half-life to several hours or days by reducing renal clearance and proteolytic degradation. The 200–400 mcg dosing range for PEG-MGF was established through community experience, calibrated to provide sustained satellite cell activation within the extended half-life window while minimizing IGF-1 family side effects.

Community-Derived Protocols

The specific dosing protocols — 200–400 mcg IM post-workout, 2–3 times per week on training days — are derived from extensive community experience rather than formal clinical trials. The training-day-only approach is grounded in MGF's biology: satellite cell activation is triggered by mechanical damage, so exogenous MGF is most effective when there is an actual repair signal to amplify.

Strength of evidence: Moderate preclinically, limited clinically. The science on MGF biology and satellite cell activation is strong and well-replicated. The specific exogenous dosing protocols for PEG-MGF in humans are based primarily on community experience and extrapolation from preclinical data. Large-scale human clinical trials for exogenous MGF injection are lacking.

Verified sources for MGF

These vendors are vetted by PeptideWiki for purity testing and COA transparency.

SwissChemsThird-party tested research peptides10% off

SwissChems10% off

Limitless BiotechPremium nootropics & research peptides15% off

Limitless Biotech15% off

CH PeptidesResearch-grade peptides with COA transparency10% off

CH Peptides10% off

View all vendor deals·Affiliate links. Commission at no extra cost.

Standard MGF / PEG-MGF Dosage Ranges

PEG-MGF is the preferred form for exogenous use due to its extended half-life. It is administered by intramuscular injection into the target muscle group, post-workout on training days only. Standard (non-PEGylated) MGF is included for completeness but is rarely used due to its impractically short half-life.

PEG-MGF Dosage by Experience Level

Level	Dose per Injection	Frequency	Weekly Total	Notes
Beginner	200 mcg IM	2x/week (training days)	400 mcg	Assess tolerance and injection technique; start conservative
Intermediate	300 mcg IM	2–3x/week (training days)	600–900 mcg	Standard protocol for most users; inject into trained muscle group
Advanced	400 mcg IM	3x/week (training days)	1,200 mcg	Upper range; diminishing returns above this dose per injection

Standard MGF (Non-PEGylated) Dosage

Level	Dose per Injection	Frequency	Timing	Notes
Standard	100–200 mcg IM	Post-workout only	Immediately post-workout (within minutes)	Split bilaterally into target muscle; half-life is only minutes

Injection Timing

PEG-MGF: Inject within 1–2 hours post-workout into the trained muscle group. The extended half-life provides a wider window than standard MGF.
Standard MGF: Inject immediately after your last set — within minutes. The half-life is so short that any delay significantly reduces effectiveness.
Training days only: MGF amplifies the satellite cell activation triggered by mechanical damage. Without a training stimulus, exogenous MGF has minimal substrate to work with.
Bilateral injection (standard MGF): For standard MGF, split the dose and inject into both sides of the target muscle (e.g., 100 mcg into each quadricep after leg training).

Training stimulus is required. Unlike some peptides that work regardless of exercise, MGF's mechanism depends on mechanical damage as the activation signal. Inject PEG-MGF only on days you trained the target muscle group. Using it on rest days wastes peptide and provides minimal benefit.

PEG-MGF vs. Standard MGF: Which to Use?

The choice between PEG-MGF and standard MGF is straightforward for most users. PEGylation transforms an impractically short-lived peptide into a viable research compound. Understanding the differences ensures you choose the right variant and adjust your protocol accordingly.

Parameter	Standard MGF	PEG-MGF
Half-Life	Minutes (very short)	Several hours to days
Injection Timing	Immediately post-workout (within minutes)	Within 1–2 hours post-workout
Typical Dose	100–200 mcg IM (bilateral)	200–400 mcg IM
Frequency	Every training session	2–3x per week (training days)
Satellite Cell Window	Brief flash of activation (minutes)	Sustained activation window (hours)
Practicality	Impractical for most users	Preferred for research use
Cost Efficiency	Poor (rapid degradation wastes peptide)	Better (sustained action per injection)
Best For	Purists wanting exact endogenous mimicry	Most users seeking practical satellite cell activation

Recommendation: PEG-MGF is the preferred choice for the vast majority of users. Its extended half-life provides a practical injection window, sustained satellite cell activation, and better overall value. Standard MGF is primarily of academic interest — its minutes-long half-life makes it impractical unless you can inject literally at the gym within seconds of finishing your set.

Calculate Your PEG-MGF Dose

PEG-MGF is supplied as a lyophilized (freeze-dried) powder, typically in 2 mg or 5 mg vials. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe. The concentration depends on how much water you add to the vial.

Worked Example:

Vial size: 2 mg (2,000 mcg) of PEG-MGF
Bacteriostatic water added: 1 mL
Concentration: 2,000 mcg ÷ 1 mL = 2,000 mcg per mL
Target dose: 200 mcg
Volume to draw: 200 ÷ 2,000 = 0.1 mL = 10 units on an insulin syringe

Quick Reference — 2 mg Vial

Bac Water Added	Concentration	200 mcg Dose	400 mcg Dose
0.5 mL	4,000 mcg/mL	5 units (0.05 mL)	10 units (0.1 mL)
1 mL	2,000 mcg/mL	10 units (0.1 mL)	20 units (0.2 mL)
2 mL	1,000 mcg/mL	20 units (0.2 mL)	40 units (0.4 mL)

Quick Reference — 5 mg Vial

Bac Water Added	Concentration	200 mcg Dose	400 mcg Dose
1 mL	5,000 mcg/mL	4 units (0.04 mL)	8 units (0.08 mL)
2 mL	2,500 mcg/mL	8 units (0.08 mL)	16 units (0.16 mL)
2.5 mL	2,000 mcg/mL	10 units (0.1 mL)	20 units (0.2 mL)
5 mL	1,000 mcg/mL	20 units (0.2 mL)	40 units (0.4 mL)

Skip the Math — Use Our

Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.

PEG-MGF Dosage by Goal

PEG-MGF's primary application is satellite cell activation for muscle repair and growth. The optimal protocol varies depending on whether you are targeting maximum muscle development, injury recovery, or general training enhancement. All protocols require a training stimulus — MGF amplifies the repair signal from exercise, so training quality matters as much as dosing.

Muscle Growth & Hypertrophy (Maximum Satellite Cell Activation)

For users seeking maximum satellite cell recruitment to support new muscle nuclei creation (hyperplasia potential) and long-term hypertrophy. Best combined with a sequential IGF-1 LR3 protocol to drive protein synthesis in the newly activated satellite cells. Requires intense, progressive resistance training as the activation signal.

Dose: 300–400 mcg PEG-MGF IM into trained muscle
Frequency: 2–3x per week (training days only)
Timing: Within 1–2 hours post-workout
Cycle: 4–6 weeks on, 4–6 weeks off
Stack: + IGF-1 LR3 40–80 mcg on off-days or several hours post-MGF injection

Muscle Repair & Injury Recovery

For users recovering from muscle strains, tears, or chronic muscle injuries where satellite cell activation can accelerate tissue repair. The localized IM injection targets satellite cells directly at the injury site. Combines well with tissue repair peptides like BPC-157 and TB-500.

Dose: 200–300 mcg PEG-MGF IM into or near the injured muscle
Frequency: 2–3x per week
Timing: Post-rehabilitation exercise or controlled loading of the injured area
Cycle: 4–6 weeks (aligned with recovery timeline)
Stack: + BPC-157 250 mcg SubQ near injury + TB-500 2–2.5 mg SubQ 2x/week for comprehensive repair

Training Enhancement & Recovery Support

A moderate protocol for users seeking enhanced recovery between training sessions and gradual improvements in muscle quality. Lower doses reduce the risk of IGF-1 family side effects while providing meaningful satellite cell support. Suitable for users who train 3–4 days per week with moderate to high volume.

Dose: 200 mcg PEG-MGF IM into trained muscle
Frequency: 2x per week (on hardest training days)
Timing: Within 1–2 hours post-workout
Cycle: 4–6 weeks on, 4–6 weeks off
Note: Focus on the muscle groups that are lagging or receive the most training volume

Tendon & Connective Tissue Support

Emerging research suggests MGF may support tendon and connective tissue healing through satellite cell-adjacent mechanisms. This is a more speculative application with less direct evidence than muscle repair. Combine with established tissue repair peptides for a comprehensive approach.

Dose: 200 mcg PEG-MGF IM near the affected tendon/joint
Frequency: 2x per week
Cycle: 4–6 weeks
Stack: + BPC-157 250 mcg SubQ near the site + TB-500 2 mg SubQ 2x/week for systemic healing support

Training quality drives results. MGF amplifies the repair signal triggered by mechanical damage. The better your training stimulus (progressive overload, adequate volume, mechanical tension), the more effectively exogenous PEG-MGF can recruit satellite cells. A mediocre training program with PEG-MGF will underperform an excellent training program without it.

MGF Injection Technique

Unlike most peptides that are injected subcutaneously, PEG-MGF is optimally administered via intramuscular (IM) injection into the target muscle group. This is because MGF's primary mechanism — satellite cell activation — is a localized effect. Delivering the peptide directly to the muscle that was trained maximizes the concentration at the site where satellite cells are being activated by exercise-induced mechanical damage.

Intramuscular Injection Guidelines

Needle gauge: 25–29 gauge insulin syringe (25–27G for larger muscles like quads and glutes; 28–29G for smaller muscles like delts and biceps)
Needle length: 0.5–1 inch depending on injection site and body composition. The needle must reach the muscle tissue, not just subcutaneous fat.
Target: Inject into the muscle group that was trained during that session — for example, quadriceps after leg day, deltoids after shoulder day
Depth: Insert the needle fully into the muscle belly at a 90-degree angle
Aspiration: Some practitioners aspirate (pull back on the plunger) briefly before injecting to check for blood vessel entry, though this is debated for small-gauge needles
Injection speed: Inject slowly and steadily over 5–10 seconds to reduce tissue trauma and pain

Preferred Injection Sites by Training Day

Training Day	Target Muscle	Injection Site	Notes
Leg Day	Quadriceps	Vastus lateralis (outer thigh)	Large, accessible muscle; rotate between both legs
Chest Day	Pectorals	Mid-chest, lateral to the nipple	Avoid the sternal midline and nipple area
Back Day	Latissimus dorsi	Lateral back, below the armpit	Difficult self-injection site; deltoids are an acceptable alternative
Shoulder Day	Deltoids	Lateral deltoid (side of shoulder)	Easy to access; rotate between both shoulders
Arm Day	Biceps / Triceps	Mid-belly of the targeted muscle	Use smaller gauge needle (28–29G) for smaller muscles

Subcutaneous Injection as an Alternative

Some users opt for subcutaneous (SubQ) injection for convenience, particularly when the target muscle is difficult to self-inject (e.g., back muscles). SubQ provides more systemic distribution, which may reduce the localized satellite cell effect but still delivers PEG-MGF to muscle tissue via circulation. If using SubQ, inject in the abdominal area or nearest subcutaneous site to the trained muscle.

Rotate injection sites. Repeated IM injection into the exact same spot can cause localized tissue irritation, scar tissue formation, and persistent soreness. Rotate within the target muscle group — for example, alternate between upper and lower quadriceps, or between the three heads of the deltoid.

Cycling Protocols

PEG-MGF is typically cycled in 4–6 week blocks aligned with training phases. Unlike GHRPs where cycling is driven by receptor desensitization, MGF cycling is primarily about maintaining the body's responsiveness to exogenous satellite cell activation signals and aligning with training periodization for maximum effect.

Standard Cycling Protocols

Protocol	On-Cycle	Off-Cycle	Notes
Conservative	4 weeks	4 weeks off	Best for first-time users; aligns with a standard training mesocycle
Standard	5 weeks	4–5 weeks off	Most common protocol; provides sufficient time for satellite cell activation and initial differentiation
Extended	6 weeks	6 weeks off	Upper recommended limit; monitor for diminishing effects in weeks 5–6
Periodization Aligned	Hypertrophy block (4–6 weeks)	Strength/deload block	Use PEG-MGF during high-volume hypertrophy phases when mechanical damage is greatest; cycle off during strength or deload phases

Aligning Cycles with Training Periodization

The most effective approach is to align PEG-MGF cycles with your training periodization. Use PEG-MGF during high-volume hypertrophy phases when mechanical muscle damage is greatest — this is when satellite cell activation provides the most benefit. Cycle off during strength phases (lower volume, higher intensity) or deload weeks when muscle damage is intentionally minimized.

Hypertrophy block (high volume): PEG-MGF ON — maximum mechanical damage creates the strongest satellite cell activation signal
Strength block (low volume, high intensity): PEG-MGF OFF — less muscle damage means less satellite cell activation to amplify
Deload week: PEG-MGF OFF — allow full recovery and receptor resensitization

Training-day-only dosing is built-in cycling. Since PEG-MGF is only used on training days (2–3x per week), you are already getting built-in rest days between doses. This is different from peptides like GHRPs that are used daily. The on/off cycling refers to multi-week blocks, not individual rest days.

PEG-MGF Stacking Protocols

PEG-MGF stacking follows one key principle: respect the biological sequence. MGF activates satellite cells first (repair signal), then other growth factors and peptides can support differentiation, hypertrophy, and tissue repair. The most effective stacks pair PEG-MGF with compounds that complement — not compete with — its satellite cell activation mechanism.

PEG-MGF + IGF-1 LR3 — The Sequential Growth Stack (Most Popular)

The gold standard MGF stack. This mimics the natural biological sequence: MGF activates and proliferates satellite cells (creating new muscle nuclei), then IGF-1 LR3 drives protein synthesis and hypertrophy in those newly created nuclei. The key is sequential timing — not simultaneous administration. PEG-MGF post-workout, then IGF-1 LR3 several hours later or on off-days.

Compound	Dose	Timing	Purpose
PEG-MGF	200–400 mcg IM	Post-workout (within 1–2 hours)	Satellite cell activation; create new muscle nuclei (hyperplasia)
IGF-1 LR3	40–80 mcg SubQ or IM	4–6 hours post-MGF, or on off-days	Protein synthesis & hypertrophy in newly activated satellite cells

Timing matters. Do NOT inject PEG-MGF and IGF-1 LR3 at the same time. IGF-1 LR3 can shift satellite cells from proliferation to differentiation prematurely, reducing the total number of new muscle nuclei created. Allow PEG-MGF several hours to activate and proliferate satellite cells before introducing IGF-1 LR3 to drive hypertrophy.

PEG-MGF + BPC-157 + TB-500 — The Comprehensive Repair Stack

For muscle injury recovery. PEG-MGF provides satellite cell activation at the injury site, BPC-157 delivers localized angiogenesis and growth factor upregulation, and TB-500 provides systemic anti-inflammatory and tissue remodeling support. Each compound addresses a different aspect of the repair process.

Compound	Dose	Route & Frequency	Purpose
PEG-MGF	200–300 mcg	IM near injury, 2–3x/week	Satellite cell activation at injury site for muscle fiber regeneration
BPC-157	250 mcg	SubQ near injury, 1–2x daily	Localized angiogenesis, growth factor upregulation, tissue repair
TB-500	2–2.5 mg	SubQ, 2x/week	Systemic anti-inflammatory, tissue remodeling, cell migration

PEG-MGF + GH Secretagogues (Comprehensive Growth Support)

Combines localized satellite cell activation with systemic GH elevation for a multi-pathway growth approach. GH secretagogues like Ipamorelin + CJC-1295 elevate GH and IGF-1 systemically, while PEG-MGF provides targeted satellite cell recruitment at the muscle level. These work through independent mechanisms and do not interfere with each other.

Compound	Dose	Frequency	Purpose
PEG-MGF	200–400 mcg IM	2–3x/week (training days, post-workout)	Localized satellite cell activation in target muscle
Ipamorelin	200–300 mcg SubQ	2–3x daily (fasted)	Systemic GH release for recovery, body composition, IGF-1 elevation
CJC-1295 (no-DAC)	100 mcg SubQ	At each Ipamorelin injection	Amplifies and sustains the GH pulse (GHRH + GHRP synergy)

No timing conflict. PEG-MGF (IM, post-workout) and GH secretagogues (SubQ, fasted) operate through completely independent mechanisms and different injection windows. The GH secretagogues should be taken fasted (morning and/or bedtime), while PEG-MGF is taken post-workout. They complement each other without interference.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Safety Profile: PEG-MGF is generally considered to have a manageable side effect profile at standard doses. As a member of the IGF-1 family, it carries theoretical risks related to growth factor signaling, including hypoglycemia and potential for uncontrolled cell growth. Long-term human safety data for exogenous MGF injection is very limited.

Common Side Effects

Dose-dependent and generally manageable:

Injection site pain, soreness, or swelling — expected with IM injection, especially in smaller muscle groups; usually resolves within 24–48 hours
Localized muscle soreness at the injection site — distinct from normal DOMS; may be more noticeable in the first few injections
Mild hypoglycemia — as an IGF-1 family peptide, PEG-MGF can lower blood sugar; symptoms include dizziness, shakiness, sweating, and lightheadedness
Localized tissue swelling around the injection area — generally mild and transient

Less common:

Fatigue or lethargy post-injection — may be related to mild hypoglycemia or immune response
Joint discomfort — reported rarely; may relate to localized growth factor effects
Headache — typically in the first few doses, resolves with continued use

Injection site reactions are the most common concern. Since PEG-MGF is administered IM rather than SubQ, injection site pain and localized soreness are more frequently reported than with subcutaneous peptides. Proper injection technique, site rotation, and appropriate needle gauge minimize these issues.

Theoretical Concerns

Uncontrolled cell growth — MGF activates satellite cells, which are stem-like cells. Theoretical concerns exist about promoting uncontrolled cell proliferation, particularly in individuals with pre-existing conditions. Long-term implications of repeated exogenous satellite cell activation are not well-studied in humans.
Localized tissue overgrowth — repeated IM injection into the same muscle with a growth factor peptide could theoretically promote asymmetric or localized tissue growth. Proper site rotation and bilateral dosing mitigate this concern.
IGF-1 family risks — as a splice variant of IGF-1, MGF shares theoretical concerns with the IGF-1 family including potential effects on insulin sensitivity and theoretical tumor promotion in susceptible individuals.

Contraindications

Active cancer or history of cancer — MGF promotes cell proliferation (satellite cell activation). Elevated growth factor signaling could theoretically support tumor growth. Avoid use with any active or suspected malignancy.
Pregnancy and breastfeeding — no safety data exists for exogenous MGF during pregnancy or nursing. Avoid entirely.
Uncontrolled diabetes — as an IGF-1 family peptide, MGF may affect blood glucose regulation. Use only with medical supervision in diabetic patients.
Active infections at the injection site — IM injection into infected tissue can spread infection and impair healing. Wait until any local infection has fully resolved.
Autoimmune conditions affecting muscle — conditions involving autoimmune attack on muscle tissue (e.g., dermatomyositis, polymyositis) may interact unpredictably with satellite cell activation. Avoid without medical guidance.

When to Stop or Reduce Dose

Persistent injection site pain or swelling that does not resolve within 48 hours
Signs of hypoglycemia (dizziness, shakiness, sweating, confusion) — have fast-acting carbohydrates available and reduce dose
Any unusual lumps or tissue changes at injection sites
Excessive localized soreness that interferes with training the target muscle
Any symptom that feels unusual or concerning — err on the side of caution

Regulatory Status: MGF and PEG-MGF are not FDA-approved for human use. They are classified as research peptides / research chemicals. They are prohibited by WADA (World Anti-Doping Agency) for competitive athletes. Regulations vary by jurisdiction — verify your local laws before purchasing.

Common PEG-MGF Dosing Mistakes

Avoid these common errors to get the most out of your PEG-MGF protocol:

Injecting PEG-MGF on rest days instead of training days: MGF’s primary mechanism is satellite cell activation in response to mechanical damage. Without exercise-induced muscle damage, there is no repair signal to amplify. Inject PEG-MGF post-workout on training days only, targeting the muscles that were trained.

Using standard MGF instead of PEG-MGF without adjusting timing: Standard MGF has a half-life of minutes — if you don’t inject immediately post-workout (within minutes of finishing), the peptide degrades before reaching satellite cells. PEG-MGF has a much wider injection window. If using standard MGF, you must inject within minutes of completing your set.

Injecting subcutaneously when intramuscular is indicated: MGF’s satellite cell activation is a localized effect. Subcutaneous injection distributes the peptide systemically, diluting the concentration at the target muscle. For maximum satellite cell recruitment, inject intramuscularly into the muscle group that was trained.

Stacking MGF with IGF-1 LR3 at the same time: IGF-1 LR3 can interfere with satellite cell proliferation if administered simultaneously with MGF. The biological sequence is: MGF first (activate and proliferate satellite cells) then IGF-1 (promote differentiation and hypertrophy). Use PEG-MGF post-workout, then IGF-1 LR3 several hours later or on off-days.

Exceeding 400 mcg per injection of PEG-MGF: Higher doses have not demonstrated proportionally greater satellite cell activation in community reports. Doses above 400 mcg increase the risk of systemic IGF-1 family side effects (hypoglycemia, localized swelling) without clear additional benefit. More is not better with MGF.

Running PEG-MGF for more than 6 weeks continuously: Extended cycles beyond 6 weeks may produce diminishing returns as the body’s response adapts. Cycling 4–6 weeks on, 4–6 weeks off allows for full receptor sensitivity restoration and aligns with standard training periodization blocks.

Injecting into a single spot repeatedly: Repeated IM injection into the same exact spot can cause localized tissue irritation, scar tissue buildup, and injection site pain. Rotate injection sites within the target muscle group — for example, different areas of the quadriceps or different heads of the deltoid.

Expecting immediate visible muscle growth: MGF activates satellite cells — a process that takes weeks to produce measurable results. Satellite cell proliferation, differentiation, and fusion with existing muscle fibers is a gradual biological process. Expect improvements in recovery quality within 1–2 weeks and potential hypertrophy contributions over 4–6 weeks of consistent use alongside progressive training.

Using MGF without a proper training stimulus: MGF is endogenously produced in response to mechanical stress. Exogenous MGF amplifies the natural satellite cell activation signal — but there must be a signal to amplify. Without progressive, challenging training that creates genuine mechanical overload, exogenous MGF has little substrate to work with.

Frequently Asked Questions

Key Takeaways

MGF is the body's natural muscle repair signal — a splice variant of IGF-1 (IGF-1Ec) produced locally in muscle tissue in response to mechanical stress
PEG-MGF is the preferred form — PEGylation extends the half-life from minutes to hours/days, making it practical for research use. Standard MGF is impractical due to its extremely short half-life.
Standard dose: 200–400 mcg PEG-MGF IM into trained muscle, 2–3x/week — inject post-workout on training days only
MGF activates satellite cells (hyperplasia) while IGF-1 LR3 promotes hypertrophy — they are complementary, not redundant. Use them sequentially, not simultaneously.
Best stack: PEG-MGF post-workout + IGF-1 LR3 hours later or on off-days — mimics the natural biological sequence of repair then growth
Intramuscular injection is preferred for localized satellite cell activation at the site of exercise-induced muscle damage
Cycle 4–6 weeks on, 4–6 weeks off — align cycles with hypertrophy training phases for maximum benefit
Training stimulus is required — MGF amplifies the repair signal from mechanical damage. Without quality training, exogenous MGF has minimal substrate to work with.
Common stacks: IGF-1 LR3 (sequential growth), BPC-157 + TB-500 (repair), GH secretagogues (comprehensive growth support)
Not FDA-approved — classified as a research peptide. Banned by WADA for competitive athletes. Check local regulations.

This article is for educational and informational purposes only. See our Disclaimer.

References

Goldspink G. “Mechanical signals, IGF-I gene splicing, and muscle adaptation.” Physiology (Bethesda). 2005;20:232-238. PubMed
Yang SY, Goldspink G. “Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation.” FEBS Lett. 2002;522(1-3):156-160. PubMed
Hill M, Goldspink G. “Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage.” J Physiol. 2003;549(Pt 2):409-418. PubMed
Hill M, et al. “The muscle regulatory gap: a novel role for the IGF-I splice variant mechano growth factor.” J Physiol. 2003;549(Pt 2):409-418. PubMed
Ates K, et al. “The IGF-I splice variant MGF increases progenitor cells in ALS, dystrophic, and normal muscle.” FEBS Lett. 2007;581(14):2727-2732. PubMed
Kandalla PK, et al. “Mechano Growth Factor E peptide (MGF-E) maintains myogenic precursor cell pool expansion in murine dystrophic muscle.” Eur J Cell Biol. 2011;90(6-7):502-507.
Mills P, et al. “A synthetic mechano growth factor E peptide administered after myocardial infarction improves cardiac function.” Heart Lung Circ. 2012;21(5):260-266.
Dluzniewska J, et al. “A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia.” FASEB J. 2005;19(13):1896-1898. PubMed
Quesada A, et al. “The E-domain of mechano growth factor promotes neuronal survival and neuro-recovery.” Mol Cell Neurosci. 2008;38(4):597-609. PubMed

Next Steps

Continue your research with these resources.

IGF-1 LR3 Dosage Guide

Learn dosing protocols for IGF-1 LR3 — the ideal sequential partner for PEG-MGF to drive hypertrophy after satellite cell activation.

Read Guide

Dosage Calculator

Calculate your exact PEG-MGF dose based on vial size and reconstitution volume.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory